Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
mRNA-1083 Composition 1 Dose A Lot A · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| mRNA-1083 Composition 1 Dose A Lot A | EXPERIMENTAL | Participants will receive single intramuscular (IM) injection of mRNA-1083 Composition 1 at Dose Level A Lot A on Day 1. |
| mRNA-1083 Composition 1 Dose A Lot B | EXPERIMENTAL | Participants will receive single IM injection of mRNA-1083 Composition 1 at Dose Level A Lot B on Day 1. |
| mRNA-1083 Composition 1 Dose B | EXPERIMENTAL | Participants will receive single IM injection of mRNA-1083 Composition 1 at Dose Level B on Day 1. |
| mRNA-1083 Composition 1 Dose C | EXPERIMENTAL | Participants will receive single IM injection of mRNA-1083 Composition 1 at Dose Level C on Day 1. |
| mRNA-1083 Composition 2 Dose A | EXPERIMENTAL | Participants will receive single IM injection of mRNA-1083 Composition 2 at Dose Level A on Day 1. |
| mRNA-1083 Composition 2 Dose B | EXPERIMENTAL | Participants will receive single IM injection of mRNA-1083 Composition 2 at Dose Level B on Day 1. |
| mRNA-1083 Composition 3 Dose A | EXPERIMENTAL | Participants will receive single IM injection of mRNA-1083 Composition 3 at Dose Level A on Day 1. |
| mRNA-1083 Composition 3 Dose B | EXPERIMENTAL | Participants will receive single IM injection of mRNA-1083 Composition 3 at Dose Level B on Day 1. |
| Influenza Vaccine | ACTIVE_COMPARATOR | Participants will receive single IM injection of Influenza Vaccine on Day 1. |
| COVID-19 Vaccine | ACTIVE_COMPARATOR | Participants will receive single IM injection of COVID-19 Vaccine on Day 1. |
| Investigational Influenza Vaccine | ACTIVE_COMPARATOR | Participants will receive single IM injection of Investigational Influenza Vaccine on Day 1. |
| Investigational COVID-19 Vaccine Lot A | ACTIVE_COMPARATOR | Participants will receive single IM injection of Investigational COVID-19 Vaccine Lot A on Day 1. |
| Investigational COVID-19 Vaccine Lot B | ACTIVE_COMPARATOR | Participants will receive single IM injection of Investigational COVID-19 Vaccine Lot B on Day 1. |
| Name | Type | Description |
|---|---|---|
| mRNA-1083 Composition 1 Dose A Lot A | BIOLOGICAL | Sterile liquid for injection |
| mRNA-1083 Composition 1 Dose A Lot B | BIOLOGICAL | Sterile liquid for injection |
| mRNA-1083 Composition 1 Dose B | BIOLOGICAL | Sterile liquid for injection |
| mRNA-1083 Composition 1 Dose C | BIOLOGICAL | Sterile liquid for injection |
| mRNA-1083 Composition 2 Dose A | BIOLOGICAL | Sterile liquid for injection |
| mRNA-1083 Composition 2 Dose B | BIOLOGICAL | Sterile liquid for injection |
| mRNA-1083 Composition 3 Dose A | BIOLOGICAL | Sterile liquid for injection |
| mRNA-1083 Composition 3 Dose B | BIOLOGICAL | Sterile liquid for injection |
| Influenza Vaccine | BIOLOGICAL | Sterile liquid for injection |
| COVID-19 Vaccine | BIOLOGICAL | Sterile liquid for injection |
| Investigational Influenza Vaccine | BIOLOGICAL | Sterile liquid for injection |
| Investigational COVID-19 Vaccine Lot A | BIOLOGICAL | Sterile liquid for injection |
| Investigational COVID-19 Vaccine Lot B | BIOLOGICAL | Sterile liquid for injection |
Inclusion Criteria: * Medically stable. * Participants who could become pregnant: negative pregnancy test and contraception for at least 28 days prior to Day 1 and for at least 90 days after the study intervention administration. * Have received ≥2 coronavirus disease 2019 (COVID-19) vaccines, with...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
mRNA-1083 Composition 1 Dose A Lot A is an investigational mRNA vaccine developed by Moderna, Inc. for influenza. It is a Phase 2 candidate in the infectious disease therapeutic area. The specific lot designation refers to a particular formulation and dose used in clinical testing.
It is being studied for influenza, and the Phase 2 trial also enrolled participants with SARS-CoV-2 as a condition, indicating the vaccine was evaluated against both influenza and COVID-19. It is an investigational product and has not been approved for use.
Moderna, Inc. (ticker MRNA) is the developer of mRNA-1083 Composition 1 Dose A Lot A. Moderna is the sponsor of the clinical program evaluating this vaccine candidate for influenza and SARS-CoV-2.
mRNA-1083 Composition 1 Dose A Lot A is in Phase 2 development. The single registered trial, NCT06864143, is listed as completed. The vaccine remains investigational and is not approved for any indication.
One trial has evaluated mRNA-1083 Composition 1 Dose A Lot A: NCT06864143, a Phase 2 study of the mRNA-1083 influenza and COVID-19 vaccine in adults 18 to under 65 years of age. It was randomized, double-blind, active-controlled, enrolled 1,320 participants in the United States, and is completed.
NCT06864143 was a randomized, double-blind, active-controlled Phase 2 trial of mRNA-1083 Composition 1 Dose A Lot A in healthy adults aged 18 to under 65 years. It enrolled 1,320 participants across United States sites and assessed immunogenicity, reactogenicity, and safety. The study is completed.